<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">88275</article-id>
<article-id pub-id-type="doi">10.7554/eLife.88275</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88275.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Stem Cells and Regenerative Medicine</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Hematopoietic Transfer of the Anti-Cancer and Lifespan-Extending Capabilities of A Genetically Engineered Blood System</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jing-Ping</given-names>
</name>
<xref ref-type="author-notes" rid="n2">#</xref>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0407-8828</contrib-id>
<name>
<surname>Hung</surname>
<given-names>Chun-Hao</given-names>
</name>
<xref ref-type="author-notes" rid="n2">#</xref>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liou</surname>
<given-names>Yao-Huei</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Ching-Chen</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yeh</surname>
<given-names>Kun-Hai</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Keh-Yang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lai</surname>
<given-names>Zheng-Sheng</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hsu</surname>
<given-names>Tzu-Chi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Tung-Liang</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Shyu</surname>
<given-names>Yu-Chiau</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hsiao</surname>
<given-names>Pei-Wen</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Liuh-Yow</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chuang</surname>
<given-names>Trees-Juen</given-names>
</name>
<xref ref-type="author-notes" rid="n2">#</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Chen-Hsin Albert</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liao</surname>
<given-names>Nah-Shih</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6515-5837</contrib-id>
<name>
<surname>Shen</surname>
<given-names>Che-Kun James</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>1</label><institution>The PhD Program for Neural Regenerative Medicine, Taipei Medical University</institution>, Taipei 115, <country>Taiwan</country></aff>
<aff id="a2"><label>2</label><institution>Institute of Molecular Biology, Academia Sinica</institution>, Nankang, Taipei 115, <country>Taiwan</country></aff>
<aff id="a3"><label>3</label><institution>Department of Nursing, Chang Gung University of Science and Technology</institution>, Taoyuan City 333, <country>Taiwan</country></aff>
<aff id="a4"><label>4</label><institution>Agricultural Biotechnology Research Center</institution>, Academia Sinica, Nankang, Taipei 115, <country>Taiwan</country></aff>
<aff id="a5"><label>5</label><institution>Graduate Institute of Life Sciences, National Defense Medical Center</institution>, Taipei 115, <country>Taiwan</country></aff>
<aff id="a6"><label>6</label><institution>Community Medicine Research Center, Chang Gung Memorial Hospital,</institution> Keelung Branch, Keelung 204, <country>Taiwan</country></aff>
<aff id="a7"><label>7</label><institution>Genomics Research Center, Academia Sinica</institution>, Nankang, Taipei 115, <country>Taiwan</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Ginzburg</surname>
<given-names>Yelena</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Icahn School of Medicine at Mount Sinai</institution>
</institution-wrap>
<city>New York</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Zaidi</surname>
<given-names>Mone</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>Icahn School of Medicine at Mount Sinai</institution>
</institution-wrap>
<city>New York</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="present-address" id="n1"><label>8</label><p>Current address-Department of Molecular Metabolism, T.H. Clan School of Public Health, Harvard University, 677 Huntington Ave, Boston, MA 02115, USA</p></fn>
<fn fn-type="equal" id="n2"><label>#</label><p>Contributed equally</p></fn>
<corresp id="cor1"><label>*</label>Corresponding Authors Please send all correspondence to: Che-Kun James Shen The PhD Program for Neural Regenerative Medicine Taipei Medical University Taipei 115, Taiwan, ROC E-mail: <email>ckshen@gate.sinica.edu.tw</email> Yu-Chiau Shyu Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung Branch, Keelung 204, Taiwan (R.O.C.) E-mail: <email>yuchiaushyu@gmail.com</email> Chun-Hao Hung The PhD Program for Neural Regenerative Medicine Taipei Medical University Taipei 115, Taiwan, ROC E-mail: <email>libur777@hotmail.com</email></corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-07-05">
<day>05</day>
<month>07</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP88275</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-04-21">
<day>21</day>
<month>04</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-04-21">
<day>21</day>
<month>04</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.04.21.537849"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Wang et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Wang et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-88275-v1.pdf"/>
<abstract>
<title>Abstract</title><p>A causal relationship exists among the aging process, organ decay and dis-function, and the occurrence of various diseases including cancer. A genetically engineered mouse model, termed <italic>Eklf</italic><sup>K74R/K74R</sup> or <italic>Eklf</italic>(K74R), carrying mutation on the well-conserved sumoylation site of the hematopoietic transcription factor KLF1/ EKLF has been generated that possesses extended lifespan and healthy characteristics including cancer resistance. We show that the high anti-cancer capability of the <italic>Eklf</italic>(K74R) mice are gender-, age-and genetic background-independent. Significantly, the anti-cancer capability and extended lifespan characteristics of <italic>Eklf</italic>(K74R) mice could be transferred to wild-type mice via transplantation of their bone marrow mononuclear cells. Targeted/global gene expression profiling analysis has identified changes of the expression of specific proteins and cellular pathways in the leukocytes of the <italic>Eklf</italic>(K74R) that are in the directions of anti-cancer and/or anti-aging. This study demonstrates the feasibility of developing a novel hematopoietic/ blood system for long-term anti-cancer and, potentially, for anti-aging.</p>
</abstract>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Aging of animals, including humans, is accompanied by lifespan-dependent organ deterioration and the occurrence of chronic diseases such as cancer, diabetes, cardiovascular failure and neurodegeneration<sup><xref ref-type="bibr" rid="c1">1</xref>, <xref ref-type="bibr" rid="c2">2</xref></sup>. To extend healthspan and lifespan, various biomedical-and biotechnology-related strategies have been intensively developed and applied, including the therapy of different diseases such as cancer<sup><xref ref-type="bibr" rid="c3">3</xref>–<xref ref-type="bibr" rid="c5">5</xref></sup>. The hematopoietic/ blood system is an important biomedical target for anti-aging and anti-cancer research development. Multiple blood cell lineages arise from hematopoietic stem cells (HSCs), with the lymphoid lineage giving rise to T, B, and natural killer (NK) cell populations, whereas the myeloid lineage differentiates into megakaryocytes, erythrocytes, granulocytes, monocytes and macrophages<sup><xref ref-type="bibr" rid="c6">6</xref>–<xref ref-type="bibr" rid="c8">8</xref></sup>. The genetic constituents and homeostasis of the hematopoietic system are regulated epigenetically and via environmental factors to maintain animal health<sup><xref ref-type="bibr" rid="c6">6</xref>, <xref ref-type="bibr" rid="c9">9</xref></sup>.</p>
<p>EKLF, also named KLF1, is a Krüppel-like factor that is expressed in a range of blood cells including erythrocytes, megakaryocytes, T cells, NK cells, as well as in various hematopoietic progenitors including common-myeloid-progenitor, megakaryocyte-erythroid-progenitor (MEP), and granulocyte-macrophage-progenitor<sup><xref ref-type="bibr" rid="c10">10</xref>–<xref ref-type="bibr" rid="c12">12</xref></sup>. The factor regulates erythropoiesis<sup><xref ref-type="bibr" rid="c13">13</xref></sup> and the differentiation of MEP to megakaryocytes and erythrocytes<sup><xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c14">14</xref></sup> as well as of monocytes to macrophages<sup><xref ref-type="bibr" rid="c15">15</xref></sup>. EKLF is also expressed in HSC and regulates their differentiation<sup><xref ref-type="bibr" rid="c16">16</xref></sup>. The factor can positively or negatively regulate transcription through binding of its zinc finger domain to the CACCC motif of the regulatory regions of a diverse array of genes<sup><xref ref-type="bibr" rid="c16">16</xref>–<xref ref-type="bibr" rid="c19">19</xref></sup>.</p>
<p>EKLF could be sumoylated <italic>in vitro</italic> and <italic>in vivo</italic>, and sumoylation of the lysine at codon 74 of mouse EKLF altered the transcriptional regulatory function<sup><xref ref-type="bibr" rid="c10">10</xref></sup> as well as nuclear import<sup><xref ref-type="bibr" rid="c20">20</xref></sup> of the factor. Surprisingly, homozygosity of a single amino acid substitution, lysine(K) to arginine(R), at the sumoylation site of EKLF results in the generation of a novel mouse model with healthy longevity. These mice, termed <italic>Eklf</italic><sup>K74R/K74R</sup> or <italic>Eklf</italic>(K74R), exhibited extended healthspan and lifespan. In particular, the <italic>Eklf</italic>(K74R) mice showed delay of the age-dependent decline of physical performance, such as the motor function and spatial learning/memory capability, and deterioration of the structure/function of tissues including the heart, liver, and kidney. Furthermore, the <italic>Eklf</italic>(K74R) mice appeared to have significantly higher anti-cancer capability than the WT mice<sup><xref ref-type="bibr" rid="c21">21</xref></sup>.</p>
<p>As described in the following, we have since characterized the high anti-cancer capability of the <italic>Eklf</italic>(K74R) mice with respect to its dependence on the age, gender and genetic background. More importantly, we have demonstrated that the high anti-cancer ability of these genetically engineered mice could be transferred to wild type mice (WT) through hematopoietic transplantation of the bone marrow mononuclear cells (BMMNC). Furthermore, we show that the higher anti-cancer capability and extended life span of <italic>Eklf</italic>(K74R) mice are associated with changes of the global protein expression profile and specific aging-/cancer-associated cellular signaling pathways in their white blood cells (WBC), or leukocytes.</p>
</sec>
<sec id="s2">
<title>Result</title>
<sec id="s2a">
<title>Characterization of the cancer resistance of Eklf(K74R) mice in relation to age, gender, and genetic background</title>
<p>The <italic>Eklf</italic>(K74R) mice appeared to be cancer resistant to carcinogenesis as manifested by their lower spontaneous cancer incidence (12.5%) in life than WT mice (75%). The <italic>Eklf</italic>(K74R) mutation also protected the mice from metastasis in the experimental metastasis assay and it reduced tumor growth in the subcutaneous cancer cell inoculation assay<sup><xref ref-type="bibr" rid="c21">21</xref></sup>. We have used the pulmonary melanoma foci assay to further characterize the higher cancer resistance of the <italic>Eklf</italic>(K74R) mice with respect to the effects of gender/age/genetic background of the mice and the requirement of the homozygous K74R mutation.</p>
<p>It appeared that male as well as female <italic>Eklf</italic>(K74R) mice in the B6 genetic background had significantly fewer pulmonary melanoma foci than the corresponding WT mice (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Because of this result, we used male mice for all of the studies describe below. First, both young (2-month-old) and aged (24-month-old) <italic>Eklf</italic>(K74R) mice had higher anti-metastasis ability against the injected melanoma cells than WT mice of age-dependent groups (<xref rid="fig1" ref-type="fig">Figure 1A</xref> and <xref rid="fig1" ref-type="fig">1B</xref>). Secondly, homozygosity of the K74R substitution was required for the higher cancer resistance of the <italic>Eklf</italic>(K74R) mice (Figure S1). Consistent with the previous study<sup><xref ref-type="bibr" rid="c21">21</xref></sup>, the <italic>Eklf</italic>(K74R) mice survived longer than the WT mice after the injection of B16-F10 cells. Importantly, the <italic>Eklf</italic>(K74R) mice in the FVB background also exhibited high cancer resistance than FVB WT mice by this assay (<xref rid="fig1" ref-type="fig">Figure 1C</xref>), suggesting that cancer resistance of <italic>Eklf</italic>(K74R) mice conferred by the homozygous K74R substitution was likely genetic background-independent. Finally, the higher anti-cancer capability of the <italic>Eklf</italic>(K74R) mice did not appear to depend on the arginine at codon 74, since <italic>Eklf</italic>(K74A) mice carrying K◊A amino acid substitution at the K74 sumoylation site also exhibited higher anti-metastasis capability than WT mice in the pulmonary foci assay (<xref rid="fig1" ref-type="fig">Figure 1D</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Anti-cancer capability of <italic>Eklf</italic>(K74R) mice as analyzed by the experimental melanoma metastasis assay.</title>
<p>(A) Flow chart illustrating the strategy of the pulmonary tumor foci assay. Left panels, representative photographs of pulmonary metastatic foci on the lungs of WT and <italic>Eklf</italic>(K74R) male mice in the B6 background two weeks after intravenous injection of B16-F10 cells (10<sup><xref ref-type="bibr" rid="c5">5</xref></sup> cells/ mouse). Statistical comparison of the numbers of pulmonary foci is shown in the two histograms on the right. N=10 (male) and N=7 (female), **, p&lt;0.01. Note that only the numbers of large pulmonary foci (&gt;1mm diameter) were scored. N&gt;6, **, p&lt;0.01. (B) Pulmonary tumor foci assay of 24-month-old WT and <italic>Eklf</italic>(K74R) male mice. Statistical comparison is shown in the two histograms. N=10 (male), *, p&lt;0.05. (C) Pulmonary tumor foci assay of male mice in the FVB background. Statistical comparison is shown in the histograph on the right. N=10, **, p&lt;0.01. (D) Pulmonary tumor foci assay of <italic>Eklf</italic>(K74A) male mice. Statistical comparison of the 3-month-old WT and <italic>Eklf</italic>(K74A) mice numbers of pulmonary foci is shown in the two histograms. N=10 (male), **, p&lt;0.01.</p></caption>
<graphic xlink:href="537849v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2b">
<title>Transfer of the anti-cancer capability and extended lifespan of Eklf(K74R) mice to WT mice via BMT</title>
<p>Since EKLF is a hematopoietic transcription factor expressed not only in mature blood cells but also in HSCs and hematopoietic stem progenitor cells, this cancer resistance may be transferable by means of BMT. This possibility was tested with uses of male mice and a standard BMT protocol<sup><xref ref-type="bibr" rid="c22">22</xref></sup>. BMMNC were purified from the bone marrow of 2-month-old CD45.2 <italic>Eklf</italic>(K74R) or WT mice and injected into the tail vein of CD45.1 WT recipient mice. Blood replacement of recipient mice with 10Gy γ-irradiation by that of the donor mice reached 90% at 7<sup>th</sup>-week (<xref rid="fig2" ref-type="fig">Figure 2A</xref> and <xref rid="fig2" ref-type="fig">2B</xref>). After 2 weeks, the recipient mice were injected with B16-F10 cells and then sacrificed a further 2 weeks later to quantify pulmonary tumor foci. We found that WT mice transplanted with WT BMMNC had similarly high numbers of tumor foci relative to WT mice without BMT (<xref rid="fig2" ref-type="fig">Figure 2C</xref> and <xref rid="fig1" ref-type="fig">1A</xref>). However, similar to <italic>Eklf</italic>(K74R) mice challenged with B16-F10 cells (<xref rid="fig1" ref-type="fig">Figure 1B</xref>), WT mice that received BMMNC from <italic>Eklf</italic>(K74R) mice presented significantly fewer tumor foci on their lungs (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Notably, BMT using 24-month-old donor mice gave similar result (Figure S2A). In order to determine if WT mice having more restricted blood replacement upon BMT from <italic>Eklf</italic>(K74R) mice still exhibited a higher anti-cancer capability, we also carried out BMT experiments with lower doses of γ-irradiation. BMT using two lower doses of γ-irradiation (2.5Gy/5Gy) still resulted in transfer of cancer resistance from <italic>Eklf</italic>(K74R) to WT mice. Approximately 40% of recipient blood cells were substituted by donor cells upon BMT with 5Gy γ-irradiation. Consequently, at that irradiation dosage, BMT from <italic>Eklf</italic>(K74R) mouse donors reduced the average number of pulmonary tumor foci in recipient WT mice to 5. On the other hand, only 20% blood replacement was achieved in the recipient mice with 2.5Gy</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Transfer of cancer resistance of <italic>Eklf</italic>(K74R) mice to WT mice by bone marrow transplantation (BMT)</title>
<p>(A) Flow chart illustrating the experimental strategy. (B) FACS analysis of the efficiency of BMT with use of 10Gy γ-irradiation. The percentages of CD45.1/CD45.2 cells in the PB of the recipient male mice were analyzed by flow cytometry, with the representative FACS charts shown on the left and the statistical histobar diagram on the right. (C) Transfer of the anti-metastasis capability of 8-week-old <italic>Eklf</italic>(K74R) male mice to age-equivalent WT male mice by BMT with use of 10Gy γ-irradiation. Left panels, representative photographs of lungs with pulmonary metastatic foci in the recipient WT (CD45.1) mice after BMT from WT (CD45.2) or <italic>Eklf</italic>(K74R) (CD45.2) donor mice and challenged with B16-F10 cells. Statistical analysis of the numbers of pulmonary B16-F10 metastatic foci on the lungs is shown in the right histogram. n=10, *, p&lt;0.05. (D) Transplantation of 8-week-old male WT (CD45.1) mice with BMMNC from age-equivalent WT (CD45.2) male mice or from <italic>Eklf</italic>(K74R) (CD45.2) male mice with use of the γ-irradiation dosage 2.5Gy or 5Gy. The histobar diagram comparing the percentages of CD45.1 and CD45.2 PB cells of the recipient WT mice after BMT is shown on the left. The statistical analysis of the average numbers of pulmonary foci on the lungs of recipient WT mice after BMT and injected with the B16-F10 cells is shown in the right histogram, N=6. **, p&lt;0.01, ***, p&lt;0.001.</p></caption>
<graphic xlink:href="537849v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>γ-irradiation (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). However, the WT mice receiving BMT from <italic>Eklf</italic>(K74R) mice again developed less number (∼10/mouse) of pulmonary tumor foci than those WT mice receiving BMT from the WT mice (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). Thus, even at a low level of 20% blood replacement, BMT still enabled effective transfer of cancer resistance from <italic>Eklf</italic>(K74R) mice to WT mice.</p>
<p>In addition, we also attempted to transfer the extended lifespan characteristics of the <italic>Eklf</italic>(K74R) mice to WT mice by BMT. Significantly, the medium lifespan of WT mice receiving BMT from <italic>Eklf</italic>(K74R) mice was 5 months longer than that of WT mice receiving BMT from WT mice (Figure S2B). Thus, the longer lifespan characteristics of the <italic>Eklf</italic>(K74R) mice was also transferable via BMT.</p>
</sec>
<sec id="s2c">
<title>Inhibition of tumor growth by transplanted BMMNC from Eklf K74R) mice</title>
<p>Our experiments indicated that <italic>Eklf</italic>(K74R) bone marrow carried the anti-metastasis capability that prevented melanoma cell colonization on the lungs of recipient mice (<xref rid="fig1" ref-type="fig">Figures. 1</xref> and <xref rid="fig2" ref-type="fig">2</xref>). To determine if <italic>Eklf</italic>(K74R) BMT could inhibit tumor growth, we examined the effect of BMT on growth of tumors with B16-F10-luc cells. As outlined in <xref rid="fig3" ref-type="fig">Figure 3A</xref>, ten days after injection of cancerous cells, the formation of bioluminescent signals in the recipient mice were confirmed by the observation of <italic>in vivo</italic> bioluminescence. The following day, we transplanted the recipient mice with BMMNC from WT or <italic>Eklf</italic>(K74R) mice and then measured the intensities of bioluminescence signals from tumors 7 and 14 days later. As shown, tumor growth in mice subjected to BMT from <italic>Eklf</italic>(K74R) mice was significantly slower relative to those receiving BMMNC from WT mice (<xref rid="fig3" ref-type="fig">Figure 3B</xref> and <xref rid="fig3" ref-type="fig">3C</xref>). Thus, <italic>Eklf</italic>(K74R) BMMNC indeed can inhibit the growth of tumor more effectively than WT BMMNC.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Inhibition of tumor growth in WT mice by BMT from <italic>Eklf</italic>(K74R) mice</title>
<p>(A) A flow chart of the experiments. Luciferase-positive B16-F10 cells were injected into the tail vein of 8-week-old WT male mice (day 0). The mice were then transplanted with BMMNC from WT or <italic>Eklf</italic>(K74R) male mice on day 11 after the luciferase-positive B16-F10 cell injection. <italic>In vivo</italic> imaging system (IVIS) was used to follow the tumor growth in mice on day 0, 10, 17 and 24, respectively. (B) Representative images of bioluminescence reflecting the luciferase activity from melanoma cancer cells in mice. The color bar indicates the scale of the bioluminescence intensity. (C) Statistical analysis of the intensities of bioluminescence in the cancer-bearing mice (WT◊WT, purple, N=7; <italic>Eklf</italic>(K74R)◊WT, blue, N=8; Control (no BMT), red, N=3).</p></caption>
<graphic xlink:href="537849v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2d">
<title>Differential expression of specific immune-, ageing-and/or cancer-associated biomolecules in the blood of Eklf(K74R) mice</title>
<p>The K74R substitution did not alter the expression levels of EKLF in the bone marrow, fetal liver<sup><xref ref-type="bibr" rid="c21">21</xref></sup> and the PB cells (Figure S1D), neither did it affect much the PB populations as shown by CBC analysis<sup><xref ref-type="bibr" rid="c21">21</xref></sup>. We further analyzed the PB populations by flow cytometry of WT and <italic>Eklf</italic>(K74R) mice of the ages 3 and 24 months, respectively. The frequency of <italic>Eklf</italic>(K74R) NK1.1<sup>+</sup> cells were higher than WT NK1.1<sup>+</sup> cells at aged mice. The latter observation correlated with the finding by Shyu <italic>et al.</italic> that the NKT cells in PB cells of 24-month-old <italic>Eklf</italic>(K74R) mice was higher than that of 24-month-old WT mice (Figure S3).</p>
<p>We first used RT-qPCR to analyze the levels in PB cells of mRNAs encoding the immune checkpoint genes (ICGs) PD-1/PD-L1<sup><xref ref-type="bibr" rid="c23">23</xref></sup> in view of the cancer resistance of <italic>Eklf</italic>(K74R) mice (<xref rid="fig4" ref-type="fig">Figure 4</xref>) as well as increased levels of PD-1 and PD-L1 in aged or tumorigenic mice<sup><xref ref-type="bibr" rid="c24">24</xref></sup>. As shown in <xref rid="fig4" ref-type="fig">Figure 4</xref>, the mRNA levels of <italic>Pd-1</italic> and <italic>Pd-l1</italic> in the PB, B cells and T cells of WT mice were both increased during aging. In great contrast, the mRNA levels and protein levels of these two genes were lower in 3-month-old <italic>Eklf</italic>(K74R) mice than the age-matched WT mice, and they remained low during ageing of the <italic>Eklf</italic>(K74R) mice. Importantly, EKLF positively regulated expression of both <italic>Pd-1</italic> and <italic>Pd-l1</italic> at the transcriptional level, as demonstrated by RNAi knockdown experiments in splenic CD3<sup>+</sup> T cells (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). As expected, lower levels of <italic>Pd-1</italic> and <italic>Pd-11</italic> expression were also observed in the PB of mice receiving BMT from <italic>Eklf</italic>(K74R) mice (Figure S2C). These findings indicate that the low tumorigenesis rate of <italic>Eklf</italic>(K74R) mice arises in part from low expression of the ICGs, <italic>Pd-1</italic> and <italic>Pd-l1</italic>.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Decrease of <italic>Pd-1</italic> and <italic>Pd-l1</italic> expression in blood cells of <italic>Eklf</italic>(K74R) mice</title>
<p>(A) Levels of <italic>Pd-1</italic> and <italic>Pd-l1</italic> mRNAs in the PB of WT and <italic>Eklf</italic>(K74R) male mice at the ages of 3 months and 24 months, respectively, as analyzed by RT-qPCR. Note the relatively low levels of <italic>Pd-1</italic> and <italic>Pd-l1</italic> mRNAs in the <italic>Eklf</italic>(K74R) mice at both ages in comparison to the WT mice. (B) Upper panels, comparison of the mRNA levels of <italic>Pd-1</italic> and <italic>Pd-l1</italic> of CD3<sup>+</sup> T cells and B220<sup>+</sup> B cells isolated from the PB of 8-week-old WT and <italic>Eklf</italic>(K74R) male mice. N=5. *, p&lt;0.05; **, p&lt;0.01. Lower panels, comparison of the protein levels of PD-1 and PD-L1, as analyzed by flow cytometry, of CD3<sup>+</sup> T cells and B220<sup>+</sup> B cells from 8-week-old WT and <italic>Eklf</italic>(K74R) male mice. N=3. *, p&lt;0.05; **, p&lt;0.01. (C) Comparison of the levels of <italic>Pd-1, Pd-l1</italic> and <italic>Eklf</italic> mRNAs, as analyzed by RT-qPCR, in CD3<sup>+</sup> T cells, which were isolated from splenocytes, without or with RNAi knockdown of <italic>Eklf</italic> mRNA. Two oligos (oligo-1 and oligo-2) were used to knockdown <italic>Eklf</italic> mRNA by ∼60-70%, which resulted in the reduction of <italic>Pd-1</italic> mRNA level by 30-60% and nearly complete depletion of <italic>Pd-l1</italic> mRNA. Control, T cells transfected with GFP-plasmid. SC, T cells transfected with scrambled oligos. N&gt;3. *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001.</p></caption>
<graphic xlink:href="537849v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We have also examined, by bead-based multiplex assay<sup><xref ref-type="bibr" rid="c25">25</xref>, <xref ref-type="bibr" rid="c26">26</xref></sup>, the expression patterns of several ageing-and/or cancer-associated cytokines. As shown in Figure S4, there was no significant difference in the serum levels of IL-1β, IL-2, IL-10, IL-12p70, INF-γ or TNF-α between WT and <italic>Eklf</italic>(K74R) mice at 24-month-old. In contrast, the level of IL-4, an anti-inflammatory cytokine<sup><xref ref-type="bibr" rid="c27">27</xref></sup> beneficial to the hippocampus of aging mice<sup><xref ref-type="bibr" rid="c28">28</xref></sup>, in 24-month-old <italic>Eklf</italic>(K74R) mice was 3-4 fold higher than the 24-month-old WT mice. On the other hand, the level of IL-6, a key factor in chronic inflammatory diseases, autoimmunity, cytokine storm and cancer<sup><xref ref-type="bibr" rid="c26">26</xref>, <xref ref-type="bibr" rid="c29">29</xref></sup>, increased only moderately during aging of the <italic>Eklf</italic>(K74R) mice (Figure S4). Thus, similar to PD-1 and PD-L1, the altered expression of some of the cytokines in the blood likely contributes to the anti-aging and/or anti-cancer characteristics of the <italic>Eklf</italic>(K74R) mice.</p>
</sec>
<sec id="s2e">
<title>Comparative proteomics analysis of the leukocytes of Eklf(K74R) mice and WT mice</title>
<p>We proceeded to examine age-dependent cell-intrinsic changes in the proteomes of the leukocytes from the WT and <italic>Eklf</italic>(K74R) mice in two different age groups. 259 and 306 differentially expressed proteins (DEPs) were identified between the two age groups for the WT and <italic>Eklf</italic>(K74R) mice, respectively (Figure S5A). To understand the correlations of these proteins with aging and cancer, we performed the GSEA and found that the age-dependent DEPs changed in the concordant direction in the WT and <italic>Eklf</italic>(K74R) mice were enriched for several known aging-related pathways, e.g. IL-6-JAK-STAT3 signaling, DNA repair, etc<sup><xref ref-type="bibr" rid="c30">30</xref></sup> (Figure S5B). Meanwhile, the age-dependent DEPs changed in the reverse directions in the WT and <italic>Eklf</italic>(K74R) mice were enriched for nine other aging-related pathways (Figure S5C).</p>
<p>We further performed DEP analyses between WT and <italic>Eklf</italic>(K74R) mice and identified strain-dependent DEPs in the two age groups. As shown in Figure S5D, only 7 DEPs were identified in the 3-month-old mice but 40 DEPs in the 24-month-old ones. Of the 40 DEPs in the elder mice, 3 and 37 were upregulated in <italic>Eklf</italic>(K74R) and WT mice, respectively (Figure S4D). Significantly, GSEA analysis of these DEPs showed that elder <italic>Eklf</italic>(K74R) leukocytes were enriched for the anti-aging pathways related to hypoxia, and p53 signaling, etc.<sup><xref ref-type="bibr" rid="c31">31</xref>, <xref ref-type="bibr" rid="c32">32</xref></sup>, while the elder WT leukocytes were enriched for the aging-associated pathways related to apoptosis, and mTORC1 signaling, etc<sup><xref ref-type="bibr" rid="c31">31</xref>, <xref ref-type="bibr" rid="c33">33</xref></sup>. On the other hand, the DEPs in elder <italic>Eklf</italic>(K74R) leukocytes were also enriched for anti-cancer pathways related to the interferon-α response, and TGF-β signaling, etc.<sup><xref ref-type="bibr" rid="c34">34</xref>–<xref ref-type="bibr" rid="c36">36</xref></sup> (Figure S5E), while DEPs in the elder WT leukocytes were enriched for the pro-cancer pathways related to IL-6-JAK-STAT3 signaling and angiogenesis<sup><xref ref-type="bibr" rid="c37">37</xref></sup>. These data together have demonstrated that <italic>Eklf</italic>(K74R) leukocytes contribute to their anti-cancer capability and long lifespan through several specific cellular signaling pathways.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Because of the complexity and intercrosses of the different pathways regulating the health and the aging process, genetic manipulation of non-human animals<sup><xref ref-type="bibr" rid="c38">38</xref>, <xref ref-type="bibr" rid="c39">39</xref></sup> and non-genetic approaches on animals including human<sup><xref ref-type="bibr" rid="c4">4</xref>, <xref ref-type="bibr" rid="c40">40</xref>, <xref ref-type="bibr" rid="c41">41</xref></sup> targeting these pathways inevitably lead to moderate-to-severe side effects such as body weight loss, adiposity, etc.. With respect to the above, the <italic>Eklf</italic>(K74R) mice<sup><xref ref-type="bibr" rid="c21">21</xref></sup> is ideal as an animal model for further insightful understanding of the ageing process as well as for biomedical development of new anti-ageing tools and approaches. Indeed, the studies reported above on the hematopoietic transfer of the anti-cancer capability and extended lifespan of <italic>Eklf</italic>(K74R) mice have demonstrated the feasibility of a novel hematopoietic blood system for anti-disease and anti-ageing.</p>
<p>The anti-cancer capability of the <italic>Eklf</italic>(K74R) mice have rendered them relatively free from spontaneous cancer occurrence<sup><xref ref-type="bibr" rid="c21">21</xref></sup>, which is also reflected by their resistance to tumorigenesis of the B16-F10 cells and LLC1 cells in the cancer-growth inhibition assay<sup><xref ref-type="bibr" rid="c21">21</xref></sup> (<xref rid="fig1" ref-type="fig">Figures. 1</xref> and <xref rid="fig3" ref-type="fig">3</xref>). Furthermore, the cancer resistance of <italic>Eklf</italic>(K74R) mice appears to be independent of the gender, age, and genetic background (<xref rid="fig1" ref-type="fig">Figure 1</xref>). The anti-metastasis property of the <italic>Eklf</italic>(K74A) mice in the pulmonary foci assay (<xref rid="fig1" ref-type="fig">Figure 1D</xref>) also indicates that the anti-cancer capability of the <italic>Eklf</italic>(K74R) mice is not due to the structural and/or post-translational properties of the arginine introduced at codon 74 of EKLF. Importantly, we have shown that the anti-cancer capability and the extended lifespan characteristics of <italic>Eklf</italic>(K74R) mice are transferrable through BMT (<xref rid="fig2" ref-type="fig">Figures. 2</xref>, <xref rid="fig3" ref-type="fig">3</xref>, and S2B). In particular, we show that BMMNC from <italic>Eklf</italic>(K74R) mice (<xref rid="fig2" ref-type="fig">Figure 2A</xref> and S2A) could confer 2-month-old WT recipient mice with the anti-cancer capability. Furthermore, ∼20% of blood substitution would allow the recipient mice to become cancer resistant in the pulmonary foci assay (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). Also, WT mice receiving BMMNC at 2-month-old <italic>Eklf</italic>(K74R) mice would live longer than those receiving WT BMMNC (Figure S2B). In interesting parallel, infusion of HSC(K74R) could extend the life span of aged WT recipient mice<sup><xref ref-type="bibr" rid="c21">21</xref></sup>. Hematopoietic stem cell therapy for different diseases<sup><xref ref-type="bibr" rid="c42">42</xref>–<xref ref-type="bibr" rid="c45">45</xref></sup> including cancer has been intensively explored and practiced such as leukemia, and neuroblastoma, etc<sup><xref ref-type="bibr" rid="c46">46</xref>, <xref ref-type="bibr" rid="c47">47</xref></sup>. Also, certain characteristics of the young mice could be transferred to old mice via heterochronic parabiosis or heterochronic transplantation<sup><xref ref-type="bibr" rid="c48">48</xref>–<xref ref-type="bibr" rid="c51">51</xref></sup>. Similarly, plasma proteins from human umbilical cord blood can revitalize hippocampal function and neuroplasticity in aged mice<sup><xref ref-type="bibr" rid="c52">52</xref>, <xref ref-type="bibr" rid="c53">53</xref></sup>. Thus, transplantation/transfer of the blood MNC carrying homozygous mutation at the sumoylation site of EKLF could be developed as a new approach for anti-cancer cell, long-term anti-aging and rejuvenation.</p>
<p>The tumorigenesis resistance and long lifespan exhibited by the <italic>Eklf</italic>(K74R) mice are most likely due to changes in the transcription regulatory properties of the mutant EKLF(K74R) protein relative to WT<sup><xref ref-type="bibr" rid="c54">54</xref></sup>. As exemplified in <xref rid="fig4" ref-type="fig">Figure 4A</xref> and <xref rid="fig4" ref-type="fig">4B</xref>, expression levels of the ICGs <italic>Pd-1</italic> and <italic>Pd-l1</italic> in the PB, B, and T cells of <italic>Eklf</italic>(K74R) mice are reduced in comparison to the WT mice. Notably, cancer incidence increases with aging<sup><xref ref-type="bibr" rid="c55">55</xref></sup>, which is accompanied by increased expression of PD-1 and PD-L1<sup><xref ref-type="bibr" rid="c56">56</xref></sup>. The lower expression of ICGs would contribute to the anti-cancer capabilities of the <italic>Eklf</italic>(K74R) blood to fight against cancer (<xref rid="fig1" ref-type="fig">Figures. 1</xref>, <xref rid="fig2" ref-type="fig">2</xref>, and 3) and to extension of the lifespan of cancer-bearing mice<sup><xref ref-type="bibr" rid="c21">21</xref></sup>. Given that EKLF is expressed in HSCs<sup><xref ref-type="bibr" rid="c16">16</xref></sup>, B cells, T cells<sup><xref ref-type="bibr" rid="c12">12</xref></sup>, NK cells and macrophages (bio-GPS database), and that RNAi knockdown of <italic>Eklf</italic> expression significantly reduced <italic>Pd-1</italic> and <italic>Pd-l1</italic> mRNA levels in splenic CD3<sup>+</sup> T cells (<xref rid="fig4" ref-type="fig">Figure 4C</xref>), we assert that this protein is an upstream transcriptional regulator of the <italic>Pd-1</italic> and <italic>Pd-l1</italic> genes and, more generally, it regulates the transcriptomes of a diverse range of hematopoietic cells. Indeed, similar to ICGs, the expression levels of several cytokines in the <italic>Eklf</italic>(K74R) blood/serum are also different from the WT blood and some of the changes during ageing or carcinogenesis in the <italic>Eklf</italic>(K74R) blood are opposite to the blood/serum of WT mice <sup><xref ref-type="bibr" rid="c26">26</xref></sup> (Figure S4).</p>
<p>Previously, the transcriptome data have been used to dissect the regulation of leukocyte aging <sup><xref ref-type="bibr" rid="c30">30</xref>, <xref ref-type="bibr" rid="c57">57</xref>, <xref ref-type="bibr" rid="c58">58</xref></sup>. In addition, proteomic analysis has revealed the signaling pathways that regulate aging of specific types of leukocyte such as the lymphocyte and neutrophils cells<sup><xref ref-type="bibr" rid="c59">59</xref>, <xref ref-type="bibr" rid="c60">60</xref></sup>. In this study, we have performed proteomics analysis of leukocytes from WT and <italic>Eklf</italic>(K74R) mice in two age groups, and found that for the elder mice, the strain-dependent DEPs in the leukocytes are enriched for a number of signaling pathways. Among these signaling pathways, at least 12 of them are closely associated with the aging process, which include hypoxia, DNA repair, etc. (Figure S5E). As summarized by the model in Figure S5F, it appears that changes of these pathways in the elder <italic>Eklf</italic>(K74R) leukocytes relative to the elder WT leukocytes are mostly in the direction of anti-aging. The data of Figure S4 together strongly suggest that the <italic>Eklf</italic>(K74R) amino acid substitution causes a change in the global gene expression profile of the leukocytes, which contributes to the high anti-cancer capability and long lifespan of the <italic>Eklf</italic>(K74R) mice.</p>
<p>In sum, we have characterized the cancer resistance of the <italic>Eklf</italic>(K74R) mice, among their other healthy characteristics, in relation to gender, age, and genetic background. We also have identified cell populations, gene expression profiles and cellular signaling pathways of the white blood cells of young and old mutant mice, in comparison to the WT ones, that are changed in the anti-cancer and/or anti-ageing directions. Finally, the transferability of the cancer resistance and extended life-span of the mutant mice via transplantation of BMMNC suggests the possibility of future development of hematopoietic blood cells genome-edited at the conserved sumoylation site of EKLF for anti-cancer and the extension of healthspan and/or lifespan in animals including human.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We thank Ya-Min Lin and her colleagues at the FACS Core for their efforts on the cell sorting. We also thank Taiwan Mouse Clinic facility for expertise help on the IVIS experiments. The effort by Dr. Ching-Yen Tsai at the Transgenic Core Facility, IMB, is greatly appreciated. The Immune Monitoring Core of Taipei Medical University provided great help in the analysis of the blood cell populations. We also thank the Bioinformatics Core Facility, IMB, for its efforts on the proteomics analysis.</p>
</ack>
<sec id="s4">
<title>Competing interests</title>
<p>The authors declare there is no conflict of interest.</p>
</sec>
<sec id="s5">
<title>Animal</title>
<p>All the animal procedures were approved by the Institute of Animal Care and Use Committees, IACUC, at Academia Sinica. The IACUC numbers are 17-02-1052, 17-12-1142, 20-10-1528, BioTReC-110-M-005, and BioTReC-111-M-004, respectively.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>C.-H.H., designed and performed experiments, analyzed data and co-wrote the helped paper.; K.-Y.W., J.-P.W. and T.-L.L. performed experiments and analyzed data.; Y.-H.L. provided technology expertise; Z.-S.L. and Y.-H.L. provided essential mouse strains and experimental knowledge.; P.-W.H. provided essential cell-line strains and experimental knowledge.; Y.-H.L., N.-S.L., and Y.-C.S., provided essential mouse strains.; C.-C.L., K.-H.Y., C.-H.A.Y. and T.-J.C. analyses of the bioinformatics data and co-wrote the paper. Y.-H.L. and N.-S.L. provided technology expertise, ideas and essential materials.; Y.-C.S. and C.-K.J.S. provided ideas, supervised the research and co-wrote the paper.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>This work was supported by Taipei Medical University (to C.-K. J. S.), Academia Sinica (to C.-K. J. S.), Chang-Gung University (CMRPG2J0341 to Y.-C. S.), and MOST grants (NSC 102-2320-B-001-010 to N.-S. L., MOST 103-2311-B-010-003 Y.-C. S., and MOST 110-2628-B-001-024 to L.-Y. C.).</p>
</sec>
<sec id="s8">
<title>Availability of data and materials</title>
<p>The data that support the findings of this study are available from the corresponding authors upon request.</p>
</sec>
<sec id="s9">
<title>Material and Methods</title>
<sec id="s9a">
<title>Mice</title>
<p>C57BL/6, B6, and FVB mice were purchased from Jackson Laboratories (Bar Harbor, Maine). The B6 <italic>Eklf</italic>(K74R), B6 <italic>Eklf</italic>(K74A) and FVB <italic>Eklf</italic>(K74R) mice were established with the assistance of the Transgenic Core Facility (TCF), IMB, Academia Sinica, Taiwan. As described previously<sup><xref ref-type="bibr" rid="c21">21</xref></sup>, the K74R mutation was introduced by homologous recombination into exon 2 (E2) of the <italic>Eklf</italic> gene of B6 mice by means of a recombinant retrovirus containing the construct loxP-PGK-gb2-neo-loxP-E2 (K74R), before excising the neomycin (neo) selection marker by crossing with Ella-Cre mice. The heterozygous <italic>Eklf</italic>(K74R/+) mice were then crossed to obtain homozygous mutant <italic>Eklf</italic>(K74R/K74R) mice, hereafter termed <italic>Eklf</italic>(K74R) mice.</p>
<p>On the other hand, <italic>Eklf</italic>(K74A) mice were generated by using the CRISPR/Cas9 system. Female B6 mice (7-to 8-week-old) were mated with B6 males and the fertilized embryos were collected from the oviducts. For oligos injection, Cas mRNA (100 ng/μl), sgRNA (50 ng/μl), and donor oligos (100 ng/μl) were mixed and injected into the zygotes at the pronuclei stage. The F0 mice were genotyped by PCR and DNA sequencing. The heterozygous <italic>Eklf</italic>(K74A/+) mice were crossed to establish the germ-line stable homozygous <italic>Eklf</italic>(K74A) F1 strain.</p>
<p><italic>Eklf</italic>(K74R) mice in the FVB background were generated using an in vitro fertilization strategy. Briefly, sperm from male B6 <italic>Eklf</italic>(K74R) mice was used to fertilize FVB mouse oocytes. In vitro fertilizations of FVB oocytes were carried out consecutively for five generations. The resulting chimeric mice with &gt;90% FVB background were then crossed with FVB mice for another five generations or more.</p>
</sec>
<sec id="s9b">
<title>Cell lines</title>
<p>Murine B16-F10 melanoma cell lines were purchased from ATCC (CRL-6475). B16-F10 cells expressing luciferase (B16-F10-luc) were generated as described previously<sup><xref ref-type="bibr" rid="c61">61</xref></sup>. All cell lines were derived from cryopreserved stocks split fewer than three times and they were confirmed as mycoplasma-free prior to use. B16-F10 cells were cultured at 37 °C and 5 % CO2 in DMEM medium supplemented with 10 % FBS, 1 % penicillin/streptomycin, and 2 mM L-glutamine. B16-F10-luc cells were selected at 37 °C and 5 % CO2 in a DMEM medium supplemented with 0.2 mg/mL zeocin (Invitrogen), 10 % FBS, 1 % penicillin/streptomycin, and 2 mM L-glutamine.</p>
</sec>
<sec id="s9c">
<title>Experimental melanoma metastasis assay</title>
<p>Cultured B16-F10 melanoma cells (1×10<sup><xref ref-type="bibr" rid="c5">5</xref></sup>, 2×10<sup><xref ref-type="bibr" rid="c5">5</xref></sup>, 5×10<sup><xref ref-type="bibr" rid="c5">5</xref></sup> cells/mouse) were injected into mouse tail vein of 8-to 9-week-old or 24-month-old <italic>Eklf</italic>(K74R) and WT mice with/ without bone marrow transplantation. Two weeks after injection, the mice were sacrificed and the number of tumor foci on their lungs was quantified<sup><xref ref-type="bibr" rid="c62">62</xref></sup>.</p>
</sec>
<sec id="s9d">
<title>Flow cytometric analysis and cell sorting</title>
<p>Single cell suspensions of the peripheral blood cells and spleen tissue of B6 mice were prepared by lysing red blood cells and then passing them through a 40-μm cell strainer (Falcon®). Bone marrow mononuclear cells (BMMNCs) were prepared as described below in the section <bold>Bone marrow transplantation (BMT)</bold>. The peripheral blood cells and splenocytes were stained extracellularly for 30 min at room temperature using different combinations of the following antibodies: anti-CD45.1 (eBioscience); anti-CD45.2 (eBioscience); anti-CD3e (eBioscience); anti-CD45R (eBioscience); anti-NK1.1 (eBioscience); anti-PD-1 (eBioscience) and anti-PD-L1 (eBioscience). The various hematopoietic progenitor cell compartments of bone marrow were also stained extracellularly for 30 min at room temperature by using different combination of the following antibodies: anti-Lineage (eBioscience), anti-c-Kit (eBioscience), anti-Sca-1 (eBioscience), anti-CD34 (eBioscience), anti-Flt-3 (eBioscience). All the immuno-stained cells were subsequently washed with 1% PBS three times and resuspended for FACS analysis and sorting. Small amounts of the cell samples were run on a FACS Analyzer LSRII-12P (BD Bioscience) to determine the proportions of different cell preparations. FACS AriaII SORP (BD Bioscience) was then used to sort the indicated cell populations. The detail gating subsets for all the cell as described above are shown in Table S1. Data analysis was performed using FlowJo software.</p>
<p>The cell population analysis of leukocytes was performed at the Immune Monitoring Core, TMU. The leukocytes of 3-or 24-month-old WT and <italic>Eklf</italic>(K74R) mice were analyzed by flow cytometry to determine the populations of CD3<sup>+</sup>-B220<sup>-</sup>-T cells, CD3<sup>-</sup>-B220<sup>+</sup>-B cells, CD3<sup>-</sup>-NK1.1<sup>+</sup>-NK cells, CD3<sup>+</sup>-B220<sup>-</sup>-CD4<sup>+</sup> helper T cells (Th), CD3<sup>+</sup>-B220<sup>-</sup>-CD8<sup>+</sup> cytotoxic T cells (Tc), CD3<sup>+</sup>-B220<sup>-</sup>-CD4<sup>+</sup>-INF-γ<sup>+</sup> (Th1), and CD3<sup>+</sup>-B220<sup>-</sup>-CD4<sup>+</sup>-IL-4<sup>+</sup> (Th2).</p>
</sec>
<sec id="s9e">
<title>RNAi knockdown of Eklf mRNA from T cells</title>
<p>CD3+ T cells isolated by sorting were cultured in RPMI 1640 medium for one day for recovery and then transfected with EGFP-plasmid (control), scrambled oligonucleotides (SC control), <italic>Eklf</italic> knockdown oligonucleotide 1 (oligo 1), or <italic>Eklf</italic> knockdown oligonucleotide 2 (oligo 2) in a 96-well plate for 48 h using a LONZA electroporation kit (P3 Primary Cell 4D-NucleofectorTM X Kit) and machine (4D-NucleofectorTM Core Unit). Then the cells were lysed using a PureLink® RNA Mini kit (Life Technologies) and analyzed by RT-qPCR.</p>
</sec>
<sec id="s9f">
<title>RT-qPCR and cell treatment</title>
<p>Total RNA from B cells, T cells, white blood cells (WBC) and total blood from the peripheral blood of <italic>Eklf</italic>(K74R) and WT mice were extracted using a PureLink® RNA Mini kit (Life Technologies). The RNAs were reverse-transcribed by means of oligo-dT primers, Maxima H Minus Reverse Transcriptase (Thermo Scientific™) and SYBR Green reagents (Applied Biosystems). RT-qPCR was performed using a LightCycler® Nano machine (Roche). Gene-specific primers for <italic>Eklf</italic>, <italic>Pd-1</italic>, <italic>Pd-l1</italic>, <italic>Pd-l2,</italic> and <italic>Gapdh</italic> were designed using Vector NTI Advance 9 software according to respective mRNA sequences in the NCBI database (primer sequences are available upon request). Expression levels of mRNAs were normalized to that of endogenous <italic>Gapdh</italic> mRNA.</p>
</sec>
<sec id="s9g">
<title>Western blotting (WB)</title>
<p>We adopted a previously described WB procedure<sup><xref ref-type="bibr" rid="c63">63</xref></sup>. White blood cells (WBC) of <italic>Eklf</italic>(K74R) and WT B6 mice were collected from RBC lysis buffer-treated peripheral blood. The WBC pellets were lysed in sample buffer and run on SDS-PAGE gels. WB with anti-EKLF (Abcam) and anti-actin (Sigma) antibodies was then used to analyze the levels of EKLF and actin protein.</p>
</sec>
<sec id="s9h">
<title>In vivo bioluminescence imaging</title>
<p><italic>Eklf</italic>(K74R) and WT B6 mice were physically restrained and 1×10<sup><xref ref-type="bibr" rid="c5">5</xref></sup> B16-F10-luc cells/mouse were intravenously injected into their tail vein. Ten days after melanoma cell inoculation, mice were anesthetized for 5 min and injected intraperitoneally with D-luciferin (300 mg/Kg of body weight). Fifteen minutes after maximum luciferin uptake, the mice were subjected to imaging of the lung and liver regions in an IVIS 50 Bioluminescence imager (Caliper Life Sciences) to determine metastatic burden. The same mice were used the next day as recipients of bone marrow transplantation (BMT) from donor WT or <italic>Eklf</italic>(K74R) mice. Following BMT, bioluminescence imaging was performed on days 0, 10, 17 and 24.</p>
</sec>
<sec id="s9i">
<title>Bone marrow transplantation (BMT)</title>
<p>BMT followed the standard protocol described in Imado <italic>et al.</italic> (2004)<sup><xref ref-type="bibr" rid="c22">22</xref></sup>. B6, CD45.1 or CD45.2 donor mice were sacrificed and their femurs were removed. Bone marrow cells were harvested by flashing the femurs with RPM I1640 medium (GIBCO) using a 27-gauge needle and syringe. The cells were then incubated at 37 °C for 30 min in murine complement buffer containing antibodies against B cells, T cells and NK cells, washed twice with PBS, and then subjected to Ficoll-Paque PLUS gradient centrifugation to collect bone marrow mononuclear cells (BMMNCs). BMMNCs (1×10<sup><xref ref-type="bibr" rid="c6">6</xref></sup> cells/mouse) from donor mice were injected into the tail veins of recipient B6, CD45.2 or CD45.1 mice that had been exposed to total body γ-irradiation of 10, 5 or 2.5 Gy.</p>
</sec>
<sec id="s9j">
<title>Bead-based multiplex assay of serum cytokines</title>
<p>Serum samples were obtained via submandibular blood collection and allowed to clot in uncoated tubes for two hours at room temperature. The tubes were centrifuged at 6,000 rpm and the supernatants were collected for cytokine analysis by bead-based multiplex assay (MILLIPLEX MAP Mouse High Sensitivity T Cell Panel, Millipore) following the manufacturer protocol<sup><xref ref-type="bibr" rid="c25">25</xref></sup>.</p>
</sec>
<sec id="s9k">
<title>Protein extraction</title>
<p>The cell pellets were resuspended in protein extraction buffer (20 mM HEPES, 0.2% SDS, 1 mM EDTA, 1 mM glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, and 2.5 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub>) with protease inhibitor cocktail (Sigma-Aldrich) and 1 mM phenylmethylsulfonyl fluoride (PMSF). The lysates were further homogenized using a Bioruptor (Diagenode) at 4 °C for 15 min, and then centrifuged at 14,000 × <italic>g</italic> at 4 °C for 20 min. The supernatant was transferred to a new tube before determining protein concentration by means of BCA protein assay (Pierce, Thermo Fisher). Protein aliquots were stored at −30 °C until use.</p>
</sec>
<sec id="s9l">
<title>In-solution digestion</title>
<p>Protein solutions were first diluted with 50 mM ammonium bicarbonate (ABC) and reduced with 5 mM dithiothreitol (DTT, Merck) at 60 °C for 45 min, followed by cysteine-blocking with 10 mM iodoacetamide (IAM, Sigma) at 25°C for 30 min. The samples were then diluted with 25 mM ABC and digested with sequencing-grade modified porcine trypsin (Promega) at 37 °C for 16 h. The peptides were desalted using a homemade C18 microcolumn (SOURCE 15RPC, GE Healthcare) and stored at −30 °C until use.</p>
</sec>
<sec id="s9m">
<title>LC-MS/MS analysis</title>
<p>The desalted peptides were diluted in HPLC buffer A (0.1% formic acid in 30% acetonitrile) and loaded onto a homemade SCX column (0.6 × 5 mm, Luna 5 µm SCX 100 Å, Phenomenex). The eluted peptides were then trapped in a reverse-phase column (Zorbax 300SB-C18, 0.3 × 5 mm; Agilent Technologies), and separated on a homemade column (HydroRP 2.5 µm, 75 μm I.D. × 15 cm with a 15 μm tip) using a multi-step gradient of HPLC buffer B (99.9% acetonitrile/0.1% formic acid) for 90 min with a flow rate of 0.3 μl/min. The LC apparatus was coupled to a 2D linear ion trap mass spectrometer (Orbitrap Elite ETD; Thermo Fisher) operated using Xcalibur 2.2 software (Thermo Fisher). Full-scan MS was performed in the Orbitrap over a range of 400 to 2,000 Da and a resolution of 120,000 at m/z 400. Internal calibration was performed using the ion signal of [Si(CH<sub>3</sub>)<sub>2</sub>O]6H<sup>+</sup> at m/z 536.165365 as lock mass. The 20 data-dependent MS/MS scan events were followed by one MS scan for the 20 most abundant precursor ions in the preview MS scan. The m/z values selected for MS/MS were dynamically excluded for 40 sec with a relative mass window of 10 ppm. The electrospray voltage was set to 2.0 kV, and the temperature of the capillary was set to 200 °C. MS and MS/MS automatic gain control was set to 1,000 ms (full scan) and 200 ms (MS/MS), or to 3 × 106 ions (full scan) and 3,000 ions (MS/MS), for maximum accumulated time or ions, respectively.</p>
</sec>
<sec id="s9n">
<title>Protein identification</title>
<p>Data analysis was carried out using Proteome Discoverer software (version 1.4, Thermo Fisher Scientific). The MS/MS spectra were searched against the SwissProt database using the Mascot search engine (Matrix Science, version 2.5). For peptide identification, 10 ppm mass tolerance was permitted for intact peptide masses, and 0.5 Da for CID fragment ions with an allowance for two missed cleavages arising from trypsin digestion, oxidized methionine and acetyl (protein N-terminal) as variable modifications, and carbamidomethyl (cysteine) as a static modification. Peptide spectrum matches (PSM) were then filtered based on high confidence and a Mascot search engine ranking of 1 for peptide identification to ensure an overall false discovery rate &lt;0.01. Proteins with single peptide hits were removed from further analysis.</p>
</sec>
<sec id="s9o">
<title>Gene Set Enrichment Analysis</title>
<p>The absolute abundance of each peptide was calculated from respective peak intensity based on the PSM abundance. The protein abundance of each sample was calculated from the sum of the peptide abundance. The abundance data were then background-corrected and normalized according to variance stabilizing transformation by using the function “normalize_vsn” in the R package <italic>DEP</italic><sup><xref ref-type="bibr" rid="c64">64</xref></sup>. Differential expression across groups was determined using the function “test_diff” based on protein-wise linear models combined with empirical Bayes statistics. Significantly differentially-expressed proteins were determined according to a P-value threshold of 0.01 and a fold-change (FC) &gt;1.5. To establish functional pathways enriched across groups, normalized data for each pair of compared groups were used to perform Gene Set Enrichment Analysis (GSEA v4.2.0)<sup><xref ref-type="bibr" rid="c65">65</xref></sup> on selected MSigDB gene sets, including Hallmark (H), curated (C2), and immunologic signature (C7) gene sets, by using the default parameters. Normalized enrichment scores (NES) were used to plot a heatmap in the R package <italic>pheatmap</italic> (v1.0.12).</p>
</sec>
<sec id="s9p">
<title>Statistical analysis</title>
<p>Data are shown as mean ± standard deviation (SD) or standard error of the mean (SEM). Comparisons of data under different experimental conditions were carried out using GraphPad Prism 6.0 software (GraphPad). Each error bar represents SEM unless otherwise indicated. Significant differences in tumor growth on mouse lungs were assessed by Student’s t test. A difference between groups was considered statistically significant when the p value was lower than 0.05.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Aman</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Schmauck-Medina</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hansen</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Autophagy in healthy aging and disease</article-title>. <source>Nat Aging</source>. Aug <year>2021</year>;<volume>1</volume>(<issue>8</issue>):<fpage>634</fpage>–<lpage>650</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s43587-021-00098-4</pub-id></mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>López-Otín</surname> <given-names>C</given-names></string-name>, <string-name><surname>Blasco</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Partridge</surname> <given-names>L</given-names></string-name>, <string-name><surname>Serrano</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kroemer</surname> <given-names>G</given-names></string-name>. <article-title>The hallmarks of aging</article-title>. <source>Cell. Jun</source> 6 <year>2013</year>;<volume>153</volume>(<issue>6</issue>):<fpage>1194</fpage>–<lpage>217</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2013.05.039</pub-id></mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Bashor</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Hilton</surname> <given-names>IB</given-names></string-name>, <string-name><surname>Bandukwala</surname> <given-names>H</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>DM</given-names></string-name>, <string-name><surname>Veiseh</surname> <given-names>O</given-names></string-name>. <article-title>Engineering the next generation of cell-based therapeutics</article-title>. <source>Nat Rev Drug Discov</source>. Sep <year>2022</year>;<volume>21</volume>(<issue>9</issue>):<fpage>655</fpage>–<lpage>675</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41573-022-00476-6</pub-id></mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Fontana</surname> <given-names>L</given-names></string-name>, <string-name><surname>Partridge</surname> <given-names>L</given-names></string-name>. <article-title>Promoting health and longevity through diet: from model organisms to humans</article-title>. <source>Cell. Mar</source> 26 <year>2015</year>;<volume>161</volume>(<issue>1</issue>):<fpage>106</fpage>–<lpage>118</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2015.02.020</pub-id></mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Longo</surname> <given-names>VD</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>RM</given-names></string-name>. <article-title>Nutrition, longevity and disease: From molecular mechanisms to interventions</article-title>. <source>Cell. Apr</source> 28 <year>2022</year>;<volume>185</volume>(<issue>9</issue>):<fpage>1455</fpage>–<lpage>1470</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2022.04.002</pub-id></mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Mitchell</surname> <given-names>E</given-names></string-name>, <string-name><surname>Spencer Chapman</surname> <given-names>M</given-names></string-name>, <string-name><surname>Williams</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title>Clonal dynamics of haematopoiesis across the human lifespan</article-title>. <source>Nature</source>. Jun <year>2022</year>;<volume>606</volume>(<issue>7913</issue>):<fpage>343</fpage>–<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-022-04786-y</pub-id></mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Pálovics</surname> <given-names>R</given-names></string-name>, <string-name><surname>Keller</surname> <given-names>A</given-names></string-name>, <string-name><surname>Schaum</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title>Molecular hallmarks of heterochronic parabiosis at single-cell resolution</article-title>. <source>Nature</source>. Mar <year>2022</year>;<volume>603</volume>(<issue>7900</issue>):<fpage>309</fpage>–<lpage>314</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-022-04461-2</pub-id></mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Seita</surname> <given-names>J</given-names></string-name>, <string-name><surname>Weissman</surname> <given-names>IL</given-names></string-name>. <article-title>Hematopoietic stem cell: self-renewal versus differentiation</article-title>. <source>Wiley Interdiscip Rev Syst Biol Med. Nov</source>-Dec <year>2010</year>;<volume>2</volume>(<issue>6</issue>):<fpage>640</fpage>–<lpage>53</lpage>. doi:<pub-id pub-id-type="doi">10.1002/wsbm.86</pub-id></mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Montazersaheb</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ehsani</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fathi</surname> <given-names>E</given-names></string-name>, <string-name><surname>Farahzadi</surname> <given-names>R</given-names></string-name>. <article-title>Cellular and Molecular Mechanisms Involved in Hematopoietic Stem Cell Aging as a Clinical Prospect</article-title>. <source>Oxid Med Cell Longev</source>. 2022;<year>2022</year>:<volume>2713483</volume>. doi:<pub-id pub-id-type="doi">10.1155/2022/2713483</pub-id></mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Frontelo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Manwani</surname> <given-names>D</given-names></string-name>, <string-name><surname>Galdass</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Novel role for EKLF in megakaryocyte lineage commitment</article-title>. <source>Blood. Dec</source> 1 <year>2007</year>;<volume>110</volume>(<issue>12</issue>):<fpage>3871</fpage>–<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2007-03-082065</pub-id></mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Nishizawa</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chonabayashi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nomura</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity</article-title>. <source>Cell Stem Cell. Sep</source> 1 <year>2016</year>;<volume>19</volume>(<issue>3</issue>):<fpage>341</fpage>–<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.stem.2016.06.019</pub-id></mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Teruya</surname> <given-names>S</given-names></string-name>, <string-name><surname>Okamura</surname> <given-names>T</given-names></string-name>, <string-name><surname>Komai</surname> <given-names>T</given-names></string-name>, <etal>et al.</etal> <article-title>Egr2-independent, Klf1-mediated induction of PD-L1 in CD4(+) T cells</article-title>. <source>Sci Rep</source>. May 4 <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>7021</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-25302-1</pub-id></mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Perkins</surname> <given-names>A</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Higgs</surname> <given-names>DR</given-names></string-name>, <etal>et al.</etal> <article-title>Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants</article-title>. <source>Blood. Apr</source> 14 <year>2016</year>;<volume>127</volume>(<issue>15</issue>):<fpage>1856</fpage>–<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2016-01-694331</pub-id></mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Neuwirtova</surname> <given-names>R</given-names></string-name>, <string-name><surname>Fuchs</surname> <given-names>O</given-names></string-name>, <string-name><surname>Holicka</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q-syndrome and in Diamond-Blackfan anemia</article-title>. <source>Ann Hematol</source>. Jan <year>2013</year>;<volume>92</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00277-012-1568-1</pub-id></mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Luo</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Ma</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wahl</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Bieker</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Crossley</surname> <given-names>M</given-names></string-name>, <string-name><surname>Montaner</surname> <given-names>LJ</given-names></string-name>. <article-title>Activation and repression of interleukin-12 p40 transcription by erythroid Kruppel-like factor in macrophages</article-title>. <source>J Biol Chem. Apr</source> 30 <year>2004</year>;<volume>279</volume>(<issue>18</issue>):<fpage>18451</fpage>–<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M400320200</pub-id></mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Hung</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Liou</surname> <given-names>YH</given-names></string-name>, <etal>et al.</etal> <article-title>Negative Regulation of the Differentiation of Flk2(-) CD34(-) LSK Hematopoietic Stem Cells by EKLF/KLF1</article-title>. <source>Int J Mol Sci. Nov</source> 10 <year>2020</year>;<volume>21</volume>(<issue>22</issue>)doi:<pub-id pub-id-type="doi">10.3390/ijms21228448</pub-id></mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Siatecka</surname> <given-names>M</given-names></string-name>, <string-name><surname>Bieker</surname> <given-names>JJ</given-names></string-name>. <article-title>The multifunctional role of EKLF/KLF1 during erythropoiesis</article-title>. <source>Blood. Aug</source> 25 <year>2011</year>;<volume>118</volume>(<issue>8</issue>):<fpage>2044</fpage>–<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2011-03-331371</pub-id></mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Pilon</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Ajay</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Kumar</surname> <given-names>SA</given-names></string-name>, <etal>et al.</etal> <article-title>Genome-wide ChIP-Seq reveals a dramatic shift in the binding of the transcription factor erythroid Kruppel-like factor during erythrocyte differentiation</article-title>. <source>Blood. Oct</source> 27 <year>2011</year>;<volume>118</volume>(<issue>17</issue>):<fpage>e139</fpage>–<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2011-05-355107</pub-id></mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Tallack</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Magor</surname> <given-names>GW</given-names></string-name>, <string-name><surname>Dartigues</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title>Novel roles for KLF1 in erythropoiesis revealed by mRNA-seq</article-title>. <source>Genome Res</source>. Dec <year>2012</year>;<volume>22</volume>(<issue>12</issue>):<fpage>2385</fpage>–<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1101/gr.135707.111</pub-id></mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Shyu</surname> <given-names>YC</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal> <article-title>Tight regulation of a timed nuclear import wave of EKLF by PKCθ and FOE during Pro-E to Baso-E transition</article-title>. <source>Dev Cell. Feb</source> 24 <year>2014</year>;<volume>28</volume>(<issue>4</issue>):<fpage>409</fpage>–<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.devcel.2014.01.007</pub-id></mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Shyu</surname> <given-names>YC</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>PC</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>TS</given-names></string-name>, <etal>et al.</etal> <article-title>Genetic Disruption of KLF1 K74 SUMOylation in Hematopoietic System Promotes Healthy Longevity in Mice</article-title>. <source>Adv Sci (Weinh</source>). Sep <year>2022</year>;<volume>9</volume>(<issue>25</issue>):<fpage>e2201409</fpage>. doi:<pub-id pub-id-type="doi">10.1002/advs.202201409</pub-id></mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Imado</surname> <given-names>T</given-names></string-name>, <string-name><surname>Iwasaki</surname> <given-names>T</given-names></string-name>, <string-name><surname>Kataoka</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title>Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation</article-title>. <source>Blood. Sep</source> 1 <year>2004</year>;<volume>104</volume>(<issue>5</issue>):<fpage>1542</fpage>–<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2003-12-4309</pub-id></mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Iwai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Hamanishi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Chamoto</surname> <given-names>K</given-names></string-name>, <string-name><surname>Honjo</surname> <given-names>T</given-names></string-name>. <article-title>Cancer immunotherapies targeting the PD-1 signaling pathway</article-title>. <source>J Biomed Sci. Apr</source> 4 <year>2017</year>;<volume>24</volume>(<issue>1</issue>):<fpage>26</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12929-017-0329-9</pub-id></mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Jiang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal> <article-title>Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape</article-title>. <source>Mol Cancer. Jan</source> 15 <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>10</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12943-018-0928-4</pub-id></mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Aira</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ruiz</surname> <given-names>T</given-names></string-name>, <string-name><surname>Dixon</surname> <given-names>L</given-names></string-name>, <string-name><surname>Blome</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rueda</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sastre</surname> <given-names>P</given-names></string-name>. <article-title>Bead-Based Multiplex Assay for the Simultaneous Detection of Antibodies to African Swine Fever Virus and Classical Swine Fever Virus</article-title>. <source>Front Vet Sci</source>. <year>2019</year>;<volume>6</volume>:<issue>306</issue>. doi:<pub-id pub-id-type="doi">10.3389/fvets.2019.00306</pub-id></mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Menees</surname> <given-names>KB</given-names></string-name>, <string-name><surname>Earls</surname> <given-names>RH</given-names></string-name>, <string-name><surname>Chung</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Sex-and age-dependent alterations of splenic immune cell profile and NK cell phenotypes and function in C57BL/6J mice</article-title>. <source>Immun Ageing. Jan</source> 8 <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>3</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12979-021-00214-3</pub-id></mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Ul-Haq</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Naz</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mesaik</surname> <given-names>MA</given-names></string-name>. <article-title>Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box</article-title>. <source>Cytokine Growth Factor Rev</source>. Dec <year>2016</year>;<volume>32</volume>:<fpage>3</fpage>–<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cytogfr.2016.04.002</pub-id></mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Boccardi</surname> <given-names>V</given-names></string-name>, <string-name><surname>Westman</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pelini</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer’s Disease</article-title>. <source>Front Aging Neurosci</source>. <year>2018</year>;<volume>10</volume>:<issue>439</issue>. doi:<pub-id pub-id-type="doi">10.3389/fnagi.2018.00439</pub-id></mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Rea</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Gibson</surname> <given-names>DS</given-names></string-name>, <string-name><surname>McGilligan</surname> <given-names>V</given-names></string-name>, <string-name><surname>McNerlan</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Alexander</surname> <given-names>HD</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>OA</given-names></string-name>. <article-title>Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines</article-title>. <source>Front Immunol</source>. <year>2018</year>;<volume>9</volume>:<issue>586</issue>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2018.00586</pub-id></mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Fabian</surname> <given-names>DK</given-names></string-name>, <string-name><surname>Fuentealba</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dönertaş</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Partridge</surname> <given-names>L</given-names></string-name>, <string-name><surname>Thornton</surname> <given-names>JM</given-names></string-name>. <article-title>Functional conservation in genes and pathways linking ageing and immunity</article-title>. <source>Immun Ageing. May</source> 14 <year>2021</year>;<volume>18</volume>(<issue>1</issue>):<fpage>23</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12979-021-00232-1</pub-id></mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Yeo</surname> <given-names>EJ.</given-names></string-name> <article-title>Hypoxia and aging</article-title>. <source>Exp Mol Med</source>. Jun 20 <year>2019</year>;<volume>51</volume>(<issue>6</issue>):<fpage>1</fpage>–<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s12276-019-0233-3</pub-id></mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>W</given-names></string-name>, <etal>et al.</etal> <article-title>Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention</article-title>. <source>Signal Transduct Target Ther. Jun</source> 28 <year>2021</year>;<volume>6</volume>(<issue>1</issue>):<fpage>245</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41392-021-00646-9</pub-id></mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Hamarsheh</surname> <given-names>S</given-names></string-name>, <string-name><surname>Groß</surname> <given-names>O</given-names></string-name>, <string-name><surname>Brummer</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zeiser</surname> <given-names>R</given-names></string-name>. <article-title>Immune modulatory effects of oncogenic KRAS in cancer</article-title>. <source>Nat Commun. Oct</source> 28 <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>5439</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-020-19288-6</pub-id></mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Ni</surname> <given-names>L</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>J</given-names></string-name>. <article-title>Interferon gamma in cancer immunotherapy</article-title>. <source>Cancer Med</source>. Sep <year>2018</year>;<volume>7</volume>(<issue>9</issue>):<fpage>4509</fpage>–<lpage>4516</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cam4.1700</pub-id></mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Principe</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Doll</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Bauer</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>TGF-β: duality of function between tumor prevention and carcinogenesis</article-title>. <source>J Natl Cancer Inst</source>. Feb <year>2014</year>;<volume>106</volume>(<issue>2</issue>):<fpage>djt369</fpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djt369</pub-id></mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Zitvogel</surname> <given-names>L</given-names></string-name>, <string-name><surname>Galluzzi</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kepp</surname> <given-names>O</given-names></string-name>, <string-name><surname>Smyth</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Kroemer</surname> <given-names>G</given-names></string-name>. <article-title>Type I interferons in anticancer immunity</article-title>. <source>Nat Rev Immunol</source>. Jul <year>2015</year>;<volume>15</volume>(<issue>7</issue>):<fpage>405</fpage>–<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri3845</pub-id></mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Zhao</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>G</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>, <etal>et al.</etal> <article-title>IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer</article-title>. <source>Oncol Rep</source>. Mar <year>2016</year>;<volume>35</volume>(<issue>3</issue>):<fpage>1787</fpage>–<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2016.4544</pub-id></mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Bin-Jumah</surname> <given-names>MN</given-names></string-name>, <string-name><surname>Nadeem</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Gilani</surname> <given-names>SJ</given-names></string-name>, <etal>et al.</etal> <article-title>Genes and Longevity of Lifespan</article-title>. <source>Int J Mol Sci</source>. Jan 28 <year>2022</year>;<volume>23</volume>(<issue>3</issue>)doi:<pub-id pub-id-type="doi">10.3390/ijms23031499</pub-id></mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Hofmann</surname> <given-names>JW</given-names></string-name>, <string-name><surname>Zhao</surname> <given-names>X</given-names></string-name>, <string-name><surname>De Cecco</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Reduced expression of MYC increases longevity and enhances healthspan</article-title>. <source>Cell. Jan</source> 29 <year>2015</year>;<volume>160</volume>(<issue>3</issue>):<fpage>477</fpage>–<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2014.12.016</pub-id></mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Ocampo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Reddy</surname> <given-names>P</given-names></string-name>, <string-name><surname>Martinez-Redondo</surname> <given-names>P</given-names></string-name>, <etal>et al.</etal> <article-title>In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming</article-title>. <source>Cell. Dec</source> 15 <year>2016</year>;<volume>167</volume>(<issue>7</issue>):<fpage>1719</fpage>–<lpage>1733.e12</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2016.11.052</pub-id></mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Varady</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Cienfuegos</surname> <given-names>S</given-names></string-name>, <string-name><surname>Ezpeleta</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gabel</surname> <given-names>K</given-names></string-name>. <article-title>Clinical application of intermittent fasting for weight loss: progress and future directions</article-title>. <source>Nat Rev Endocrinol</source>. May <year>2022</year>;<volume>18</volume>(<issue>5</issue>):<fpage>309</fpage>–<lpage>321</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41574-022-00638-x</pub-id></mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Hifumi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Yamamoto</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ato</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Clinical Serum Therapy: Benefits</article-title>, <source>Cautions, and Potential Applications. Keio J Med. Dec</source> 25 <year>2017</year>;<volume>66</volume>(<issue>4</issue>):<fpage>57</fpage>–<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.2302/kjm.2016-0017-IR</pub-id></mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Morgan</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Gray</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lomova</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kohn</surname> <given-names>DB</given-names></string-name>. <article-title>Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned</article-title>. <source>Cell Stem Cell. Nov</source> 2 <year>2017</year>;<volume>21</volume>(<issue>5</issue>):<fpage>574</fpage>–<lpage>590</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.stem.2017.10.010</pub-id></mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Giannaccare</surname> <given-names>G</given-names></string-name>, <string-name><surname>Carnevali</surname> <given-names>A</given-names></string-name>, <string-name><surname>Senni</surname> <given-names>C</given-names></string-name>, <string-name><surname>Logozzo</surname> <given-names>L</given-names></string-name>, <string-name><surname>Scorcia</surname> <given-names>V</given-names></string-name>. <article-title>Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review</article-title>. <source>Ophthalmol Ther</source>. Jun <year>2020</year>;<volume>9</volume>(<issue>2</issue>):<fpage>235</fpage>–<lpage>248</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40123-020-00239-9</pub-id></mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Fu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>YZ</given-names></string-name>, <string-name><surname>Shao</surname> <given-names>ZM</given-names></string-name>. <article-title>Natural killer cells in cancer biology and therapy</article-title>. <source>Mol Cancer. Aug</source> 6 <year>2020</year>;<volume>19</volume>(<issue>1</issue>):<fpage>120</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12943-020-01238-x</pub-id></mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Daver</surname> <given-names>N</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Pollyea</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Fathi</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Vyas</surname> <given-names>P</given-names></string-name>, <string-name><surname>DiNardo</surname> <given-names>CD</given-names></string-name>. <article-title>New directions for emerging therapies in acute myeloid leukemia: the next chapter</article-title>. <source>Blood Cancer J. Oct</source> 30 <year>2020</year>;<volume>10</volume>(<issue>10</issue>):<fpage>107</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41408-020-00376-1</pub-id></mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Mora</surname> <given-names>J</given-names></string-name>. <article-title>Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review</article-title>. <source>Cancers (Basel). May</source> 24 <year>2022</year>;<volume>14</volume>(<issue>11</issue>)doi:<pub-id pub-id-type="doi">10.3390/cancers14112572</pub-id></mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Conboy</surname> <given-names>IM</given-names></string-name>, <string-name><surname>Conboy</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Wagers</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Girma</surname> <given-names>ER</given-names></string-name>, <string-name><surname>Weissman</surname> <given-names>IL</given-names></string-name>, <string-name><surname>Rando</surname> <given-names>TA</given-names></string-name>. <article-title>Rejuvenation of aged progenitor cells by exposure to a young systemic environment</article-title>. <source>Nature. Feb</source> 17 <year>2005</year>;<fpage>433</fpage>(7027):760-4. doi:10.1038/nature03260</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Das</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Godoy</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Young bone marrow transplantation preserves learning and memory in old mice</article-title>. <source>Commun Biol</source>. <year>2019</year>;<volume>2</volume>:<issue>73</issue>. doi:<pub-id pub-id-type="doi">10.1038/s42003-019-0298-5</pub-id></mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Goodell</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Rando</surname> <given-names>TA.</given-names></string-name> <article-title>Stem cells and healthy aging</article-title>. <source>Science</source>. Dec 4 <year>2015</year>;<volume>350</volume>(<issue>6265</issue>):<fpage>1199</fpage>–<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aab3388</pub-id></mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Kang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Moser</surname> <given-names>VA</given-names></string-name>, <string-name><surname>Svendsen</surname> <given-names>CN</given-names></string-name>, <string-name><surname>Goodridge</surname> <given-names>HS</given-names></string-name>. <article-title>Rejuvenating the blood and bone marrow to slow aging-associated cognitive decline and Alzheimer’s disease</article-title>. <source>Commun Biol. Feb</source> 13 <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<fpage>69</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s42003-020-0797-4</pub-id></mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Castellano</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Mosher</surname> <given-names>KI</given-names></string-name>, <string-name><surname>Abbey</surname> <given-names>RJ</given-names></string-name>, <etal>et al.</etal> <article-title>Human umbilical cord plasma proteins revitalize hippocampal function in aged mice</article-title>. <source>Nature. Apr</source> 27 <year>2017</year>;<volume>544</volume>(<issue>7651</issue>):<fpage>488</fpage>–<lpage>492</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature22067</pub-id></mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Mehdipour</surname> <given-names>M</given-names></string-name>, <string-name><surname>Skinner</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal> <article-title>Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin</article-title>. <source>Aging (Albany NY). May</source> 30 <year>2020</year>;<volume>12</volume>(<issue>10</issue>):<fpage>8790</fpage>–<lpage>8819</lpage>. doi:<pub-id pub-id-type="doi">10.18632/aging.103418</pub-id></mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Siatecka</surname> <given-names>M</given-names></string-name>, <string-name><surname>Xue</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bieker</surname> <given-names>JJ</given-names></string-name>. <article-title>Sumoylation of EKLF promotes transcriptional repression and is involved in inhibition of megakaryopoiesis</article-title>. <source>Mol Cell Biol</source>. Dec <year>2007</year>;<volume>27</volume>(<issue>24</issue>):<fpage>8547</fpage>–<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1128/mcb.00589-07</pub-id></mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Aunan</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>WC</given-names></string-name>, <string-name><surname>Søreide</surname> <given-names>K</given-names></string-name>. <article-title>The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks</article-title>. <source>Aging Dis</source>. Oct <year>2017</year>;<volume>8</volume>(<issue>5</issue>):<fpage>628</fpage>–<lpage>642</lpage>. doi:<pub-id pub-id-type="doi">10.14336/ad.2017.0103</pub-id></mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Lages</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Lewkowich</surname> <given-names>I</given-names></string-name>, <string-name><surname>Sproles</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wills-Karp</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chougnet</surname> <given-names>C</given-names></string-name>. <article-title>Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway</article-title>. <source>Aging Cell</source>. Oct <year>2010</year>;<volume>9</volume>(<issue>5</issue>):<fpage>785</fpage>–<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1474-9726.2010.00611.x</pub-id></mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Schaum</surname> <given-names>N</given-names></string-name>, <string-name><surname>Lehallier</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hahn</surname> <given-names>O</given-names></string-name>, <etal>et al.</etal> <article-title>Ageing hallmarks exhibit organ-specific temporal signatures</article-title>. <source>Nature</source>. Jul <year>2020</year>;<volume>583</volume>(<issue>7817</issue>):<fpage>596</fpage>–<lpage>602</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2499-y</pub-id></mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Aira</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ruiz</surname> <given-names>T</given-names></string-name>, <string-name><surname>Dixon</surname> <given-names>L</given-names></string-name>, <string-name><surname>Blome</surname> <given-names>S</given-names></string-name>, <string-name><surname>Rueda</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sastre</surname> <given-names>P</given-names></string-name>. <article-title>Bead-Based Multiplex Assay for the Simultaneous Detection of Antibodies to African Swine Fever Virus and Classical Swine Fever Virus. Original Research</article-title>. <source>Frontiers in Veterinary Science</source>. <year>2019</year>-September-13 2019;6doi:<pub-id pub-id-type="doi">10.3389/fvets.2019.00306</pub-id></mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>C</given-names></string-name>, <string-name><surname>Sun</surname> <given-names>H</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>. <article-title>Proteomic profiling of lymphocytes in autoimmunity, inflammation and cancer</article-title>. <source>J Transl Med. Jan</source> 7 <year>2014</year>;<volume>12</volume>:<issue>6</issue>. doi:<pub-id pub-id-type="doi">10.1186/1479-5876-12-6</pub-id></mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>G</given-names></string-name>, <string-name><surname>Manwani</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Neutrophil ageing is regulated by the microbiome</article-title>. <source>Nature. Sep</source> 24 <year>2015</year>;<volume>525</volume>(<issue>7570</issue>):<fpage>528</fpage>–<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature15367</pub-id></mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Tsai</surname> <given-names>CH</given-names></string-name>, <string-name><surname>Tzeng</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Chao</surname> <given-names>TK</given-names></string-name>, <etal>et al.</etal> <article-title>Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells</article-title>. <source>Cancer Res. Oct</source> 1 <year>2016</year>;<volume>76</volume>(<issue>19</issue>):<fpage>5756</fpage>–<lpage>5767</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.Can-16-0641</pub-id></mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Narasimhan</surname> <given-names>PB</given-names></string-name>, <string-name><surname>Eggert</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>YP</given-names></string-name>, <etal>et al.</etal> <article-title>Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases</article-title>. <source>J Immunol. Jan</source> 1 <year>2020</year>;<volume>204</volume>(<issue>1</issue>):<fpage>192</fpage>–<lpage>198</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1900998</pub-id></mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="other"><string-name><surname>Green</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Sambrook</surname> <given-names>J</given-names></string-name>. <source>Molecular Cloning: A Laboratory Manual</source>. <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>; <year>2012</year>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Smits</surname> <given-names>AH</given-names></string-name>, <string-name><surname>van Tilburg</surname> <given-names>GB</given-names></string-name>, <string-name><surname>Ovaa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Huber</surname> <given-names>W</given-names></string-name>, <string-name><surname>Vermeulen</surname> <given-names>M</given-names></string-name>. <article-title>Proteome-wide identification of ubiquitin interactions using UbIA-MS</article-title>. <source>Nat Protoc</source>. Mar <year>2018</year>;<volume>13</volume>(<issue>3</issue>):<fpage>530</fpage>–<lpage>550</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nprot.2017.147</pub-id></mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Subramanian</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tamayo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mootha</surname> <given-names>VK</given-names></string-name>, <etal>et al.</etal> <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A. Oct</source> 25 <year>2005</year>;<volume>102</volume>(<issue>43</issue>):<fpage>15545</fpage>–<lpage>50</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88275.1.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ginzburg</surname>
<given-names>Yelena</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Icahn School of Medicine at Mount Sinai</institution>
</institution-wrap>
<city>New York</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Incomplete</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Useful</kwd>
</kwd-group>
</front-stub>
<body>
<p>Wang et al present a <bold>useful</bold> manuscript that builds modestly on the group's previous publication on KLF1 (EKLF) K47R mice focused on understanding how Eklf mutation confers anticancer and longevity advantages in vivo (Shyu et al., Adv Sci (Weinh). 2022). The data demonstrates that Eklf (K74R) imparts these advantages in a background, age, and gender independent manner, not the consequence of the specific amino acid substitution, and transferable by BMT. However, the authors overstate the meaning of these results and the strength of evidence is <bold>incomplete</bold>, since only a melanoma model of cancer is used, it is unclear why only homozygous mutation is needed when only a small fraction of cells during BMT confer benefit, they do not show EKLF expression in any cells analyzed, and the PD-1 and PDL-1 experiments are not conclusive. The definitive mechanism relative to the prior publication from this group on this topic remains unclear.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88275.1.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The authors Wang et al. present a study of a mouse model K74R that they claim can extend the life span of mice, and also has some anti-cancer properties. Importantly, this mechanism seems to be mediated by the hematopoietic system, and protective effects can be transferred with bone marrow transplantation.</p>
<p>The authors need to be more specific in the title and abstract as to what is actually novel in this manuscript (a single tumor model), and what relies on previously published data (lifespan). Because many of these claims derive from previously published data, and the current manuscript is an extension of previously published work. The authors need to be more specific as to the actual data they present (they only use the B16 melanoma model) and the actual novelty of this manuscript.</p>
<p>Especially experiments on life span are published and not sufficiently addressed in this actual paper, as the title would suggest.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88275.1.sa1</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The manuscript by Wang et al. follows up on the group's previous publication on KLF1 (EKLF) K47R mice and reduced susceptibility to tumorigenesis and increased life span (Shyu et al., Adv Sci (Weinh). Sep 2022;9(25):e2201409. doi:10.1002/advs.202201409). In the current manuscript, the authors have described the dependence of these phenotypes on age, gender, genetic background, and hematopoietic translation of bone marrow mononuclear cells. Considering the current study is centered on the phenotypes described in the previous study, the novelty is diminished. Further, there are significant conceptual concerns in the study that make the inferences in the manuscript far less convincing. Major concerns are listed below:</p>
<p>1. The authors mention more than once in the manuscript that KLF1 is expressed in range of blood cells including hematopoietic stem cells, megakaryocytes, T cells and NK cells. In the case of megakaryocytes, studies from multiple labs have shown that while EKLF is expressed megakaryocyte-erythroid progenitors, EKLF is important for the bipotential lineage decision of these progenitors, and its high expression promotes erythropoiesis, while its expression is antagonized during megakaryopoiesis. In the case of HSCs, the authors reference to their previous publication for KLF1's expression in these cells- however, in this study nor in the current study, there is no western blot documented to convincingly show that KLF1 protein is expressed at detectable levels in these cells. For T cells, the authors have referenced a study which is based on ectopic expression of KLF1. For NK cells, the authors reference bioGPS: however, upon inspection, this is also questionable.</p>
<p>2. The current study rests on the premise that KLF1 is expressed in HSCs, NK cells and leukocytes, and the references cited are not sufficient to make this assumption, for the reasons mentioned in the first point. Therefore, the authors will have to show both KLF1 mRNA and protein levels in these cells, and also compare them to the expression levels seen in KLF1 wild type erythroid cells along with knockout erythroid cells as controls, for context and specificity.</p>
<p>3. To get to the mechanism driving the reduced susceptibility to tumorigenesis and increased life span phenotypes in EKLF K74R mice, the authors report some observations- However, how these observations are connected to the phenotypes is unclear.</p>
<p>
a. For example, in Figure S3, they report that the frequency of NK1.1+ cells is higher in the mutant mice. The significance of this in relation to EKLF expression in these cells and the tumorigenesis and life span related phenotypes are not described. Again, as mentioned in the second point, KLF1 protein levels are not shown in these cells.</p>
<p>
b. In Figure 4, the authors show mRNA levels of immune check point genes, PD-1 and PD-l1 are lower in EKLF K74R mice in PB, CD3+ T cells and B220+ B cells. Again, the questions remain on how these genes are regulated by EKLF, and whether and at what levels EKLF protein is expressed in T cells and B cells relative to erythroid cells. Further, while the study they reference for EKLF's role in T cells is based on ectopic expression of EKLF in CD4+ T cells, in the current study, CD3+ T cells are used. Also, there are no references for the status of EKLF in B cells. These details are not discussed in the manuscript.</p>
<p>4. The authors perform comparative proteomics in the leukocytes of EKLF K74R and WT mice as shown in Figure S5. What is the status of EKLF levels in the mutant lysate vs wild type lysates based on this analysis? More clarity needs to be provided on what cells were used for this analysis and how they were isolated since leukocytes is a very broad term.</p>
<p>5. In the discussion the authors make broad inferences that go beyond the data shown in the manuscript. They mention that the tumorigenesis resistance and long lifespan is most likely due to changes in transcription regulatory properties and changes in global gene expression profile of the mutant protein relative to WT leukocytes. And based on reduced mRNA levels of Pd-1 Pd-l1 genes in the CD3+ T cells and B220+ B cells from mutant mice, they &quot;assert&quot; that EKLF is an upstream regulator of these genes and regulates the transcriptomes of a diverse range of hematopoietic cells. The lack of a ChIP assay to show binding of WT EKLF on genes in these cells and whether this binding is reduced or abolished in the mutant cells, make the above statements unsubstantiated.</p>
<p>6. Where westerns are shown, the authors need to show the molecular weight ladder, and where qPCR data are shown for EKLF, it will be helpful to show the absolute levels and compare these levels to those in erythroid cells, along the corresponding EKLF knock out cells as controls.</p>
<p>7. Figure S1D does not have a figure legend. Therefore, it is unclear what the blot in this figure is showing. In the text of the manuscript where they reference this figure, they mention that the levels of the mutant EKLF vs WT EKLF does not change in peripheral blood, while in the figure they have labeled WBCs for the blot, and the mRNA levels shown do seem to decrease in the mutant compared to WT peripheral blood.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.88275.1.sa0</article-id>
<title-group>
<article-title>Reviewer #3 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Hung et al provide a well-written manuscript focused on understanding how Eklf mutation confers anticancer and longevity advantages in vivo. The work is fundamental and the data is convincing although several details remain incompletely elucidated. The major strengths of the manuscript include the clarity of the effect and the appropriate controls. For instance, the authors query whether Eklf (K74R) imparts these advantages in a background, age, and gender dependent manner, demonstrating that the findings are independent. In addition, the authors demonstrate that the effect is not the consequence of the specific amino acid substitution, with a similar effect on anticancer activity. Furthermore, the authors provide some evidence that PD-1 and PDL-1 are altered in Eklf (K74R) mice.</p>
<p>Finally, they demonstrate that the effects are transferrable with BMT. Several weaknesses are also evidence. For instance, only melanoma is tested as a model of cancer such that a broad claim of &quot;anti-cancer activity&quot; may be somewhat of an overreach. It is also unclear why a homozygous mutation is needed when only a small fraction of cells during BMT can confer benefit. It is also difficult to explain how transplanted donor Eklf (K74R) HSCs confer anti-melanoma effect 7 and 14 days after BMT. Furthermore, it would be useful to see whether there are virulence marker alterations in the melanoma loci in WT vs Eklf (K74R) mice. Finally, the data in Fig 4c is difficult to interpret as decreased PD-1 and PDL-1 after knockdown of EKLF in vitro is not a useful experiment to corroborate how mutation without changing EKLF expression impacts immune cells. The work is impactful as it provides evidence that healthspan and lifespan may be modulated by specific hematological mutation but the mechanism by which this occurs is not completely elucidated by this work.</p>
</body>
</sub-article>
</article>